The Australian clinical research landscape is primed for early phase research development for emerging biopharma.
Australia's reputation as a leading global destination for early phase clinical trials is well established. A two-decade-long strategy has created a nation with a strong talent pool and infrastructure network, streamlined regulatory framework, and globally accepted data, to create a keenly competitive clinical research industry.
But for an emerging biopharma (EBP), is it the right choice? As with any life sciences company, but especially true for EBPs, the need to maximize investment and resource is paramount to success. Common practice amongst EBPs, as well as larger biopharma companies, is to partner with a service provider to deliver the necessary expertise and support. This can extend to navigating regulatory complexities, therapeutic knowledge, global market ambitions as well as achieve its strategic objectives.
Fully realizing Australia's potential for an organization requires careful planning and expert local advice. Download the paper to find out more.